Clinical trials: Histological Response
Melanoma
Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI
The goals of this study are to 1) assess the safety of recombinant MAGE-A3 protein combined with AS15 Immunological Adjuvant System (recMAGE-A3 + AS15) as an Antigen-Specific Cancer Immunotherapeutic (MAGE-A3 ASCI) when…
- Trial name
- Mel55 (NCT01425749)
- Testing
- recMAGE-A3 + AS15 ASCI
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Craig L Slingluff, Jr
Nasopharyngeal Carcinoma, Head and Neck Cancer
Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
Head and neck squamous cell carcinoma (SCC) is the sixth most common cancer worldwide, with more than 700,000 new cases and more than 350,000 deaths each year.
- Conditions
- Nasopharyngeal Carcinoma, Head and Neck Cancer, Radiotherapy-induced Oral Mucositis, Biomarker
- Trial name
- NCT06307314
- Where
- 5 sites in China
- Volunteers
- 300 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes.
- Conditions
- Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer
- Trial name
- PROPHETIC (NCT04056247)
- Testing
- Plasma sample collection
- Where
- 41 sites in United States, Germany and 3 more
- Volunteers
- 10,000 people
- Sponsor
- OncoHost Ltd.
Melanoma
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine
The goal of this clinical research study is to find the best dosing schedule of a combined treatment of PEG Intron® (pegylated Interferon-alfa 2b) plus a peptide vaccine (gp100) that may help improve immune response in patients…
- Trial name
- NCT00861406
- Testing
- Pegylated Interferon-Alfa 2b (PEG Intron), GP-100 Peptide Vaccine
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Carcinoma
RNA-Loaded Dendritic Cell Cancer Vaccine
The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of administering a dendritic cell vaccine to patients with metastatic renal cell carcinoma.
- Trial name
- NCT00087984
- Testing
- MB-002
- Where
- 5 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Argos Therapeutics
Liver Cancer
Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a new surgical procedure that induces rapid liver regeneration in patients with small liver remnant planning for major liver resection.
- Trial name
- NCT04868149
- Testing
- Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- The University of Hong Kong
Head and Neck Squamous Cell Carcinoma
Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study
This is a prospective, single-arm, multi-center, Phase II clinical trial evaluating the efficacy and safety of neoadjuvant becotatug vedotin (an anti-EGFR antibody-drug conjugate) combined with pucotenlimab (HX008, an anti-PD-1…
- Trial name
- GATEWAY (NCT07589049)
- Testing
- Becotatug Vedotin, Pucotenlimab
- Where
- 12 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer, Melanoma
PD-L1 Expression in Cancer (PECan Study).
Measurement of PD-L1 expression in cancer to monitor treatment response. A prospective non-blinded, single centre, single interventional arm diagnostic imaging study.
- Trial name
- PECan (NCT04436406)
- Testing
- [99mTc]-NM-01 SPECT/CT
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Stress, Job, PTSD
The Sequestration of Holistic Stress Management Techniques for Adults
This remote study is intended to assist the population with access to cost-effective pastoral counseling for stress management in the workplace and every day life.
- Conditions
- Stress, Job, PTSD, Hypervigilance, Hyperthyroidism
- Trial name
- NCT06098755
- Testing
- Holistic Medicine (HM)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Goddess Zena I. Jones
Sarcoma
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) scan and computated tomography (CT) scan, may help doctors predict a patient's response to treatment and may help plan the best treatment.
- Trial name
- NCT00346125
- Testing
- pegfilgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal Large B-cell Lymphoma
Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the efficacy and safety of MDV9300 in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have achieved either stable disease or a partial remission following…
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal Large B-cell Lymphoma, Transformed Indolent Lymphoma
- Trial name
- NCT02653989
- Testing
- MDV9300
- Where
- United States
- Sponsor
- Medivation, Inc.
B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission
Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate
This laboratory study is looking at response or resistance to chemotherapy in young patients with acute lymphoblastic leukemia treated with methotrexate.
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT00898404
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Oncology Group
Follicular Lymphoma, Non-Hodgkin's Lymphoma
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
Background: The disease follicular lymphoma (FL) develops when the body makes abnormal B-cells. These cells usually build up in the lymph nodes, but can also affect other parts of the body.
- Conditions
- Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL
- Trial name
- NCT03789240
- Testing
- Rituximab, Copanlisib, Bone Marrow Aspiration/Biopsy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Osteosarcoma
Development of Indices Predicting Response to Pre-operative Chemotherapy in Osteosarcoma Patients
The purpose of this study is to develop indices predicting response to pre-operative chemotherapy in osteosarcoma patients. Histologic response to pre-operative chemotherapy is very important for the ultimate outcome of…
- Trial name
- NCT00686738
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- National Cancer Center, Korea
Sepsis, Acute Myeloid Leukemia
Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid Leukemia
Acute leukemia is a life threatening illness that strikes people of all ages. In addition to surviving the direct effects of the disease, the treatment of leukemia generally requires chemotherapy which has its own burden.
- Trial name
- AML (NCT00806325)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Ohio State University
Renal Cell Carcinoma, Hereditary Leiomyomatosis
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Background: There are no established treatments for people with certain advanced kidney cancers. These tumors often don't respond well to currently available treatments.
- Conditions
- Renal Cell Carcinoma, Hereditary Leiomyomatosis, Renal Cell Cancer
- Trial name
- NCT02495103
- Testing
- Vandetanib, Metformin, Vandetanib/Metformin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma
Immune Response Evaluation to Curative Conventional Therapy
The IRECT trial is a non-interventional, prospective clinical trial using modern immune monitoring techniques over the course of the standard of care for HNSCC.
- Trial name
- IRECT-01 (NCT03053661)
- Volunteers
- 22 people
- Sponsor
- University of Ulm
Renal Cell Carcinoma
Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)
The purpose of this study is to assess magnetic resonance imaging (MRI) as a tool to track tumor growth for renal cell carcinoma while the participant is receiving clinical treatment therapy with sunitinib or pazopanib.
- Trial name
- NCT00749320
- Testing
- Arterial Spin Labeling Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Beth Israel Deaconess Medical Center
Brain Cancer, Meningioma
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
This trial is a paucicentric, clinico-biological cohort study with retrospective and prospective enrollment, aiming to identify biomarkers predictive of response to Proton Beam Therapy (PBT) in cancer patients (high grade…
- Conditions
- Brain Cancer, Meningioma, Sarcoma
- Trial name
- PROTONBIOMARKS (NCT04367779)
- Where
- 2 sites in France
- Volunteers
- 84 people
- Sponsor
- Centre Leon Berard
Epithelial Ovarian Cancer, Primary Peritoneal Cancer
Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer
Clinically, there has been extensive experience with topotecan and cisplatin. Recently, several investigators have evaluated the combination of paclitaxel, cisplatin and topotecan.
- Trial name
- NCT00314678
- Testing
- Topotecan, Cisplatin, Paclitaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- John P. Fruehauf
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.